Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment 2023-06-02 00:06
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan 2023-05-17 21:13
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine 2023-04-28 00:29
Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program 2023-04-12 16:25
Sirnaomics Announces 2022 Annual Results 2023-03-28 19:26
Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit 2023-03-20 23:27
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting 2023-02-07 16:34
Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers 2023-02-01 15:00
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors 2022-12-21 00:39
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ 2022-12-14 23:47
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022 2022-12-14 01:41
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022 2022-12-14 01:40
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment 2022-11-08 05:13
Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences 2022-10-19 14:55
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference 2022-09-20 22:40
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum 2022-09-07 11:32
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma 2022-08-29 15:59
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases 2022-08-26 21:54
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes 2022-08-22 08:33
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ 2022-08-19 13:31
1 2 3